Form 4: BioLargo Director Receives Stock Options as Compensation for Board Service
SEC Form 4 Filing
Christina Bray, a director at BioLargo, Inc., received stock options as compensation for her board service during the most recent quarterly period.
Summary
- On December 31, 2024, Christina Bray, a director of BioLargo, Inc., was granted an option to purchase 98,684 shares of common stock at an exercise price of $0.19 per share.
- This option was issued as payment for $18,750 in fees for her service on the board of directors for the most recently completed quarterly period.
- The options vest immediately and expire on December 31, 2034.
- Following this transaction, Ms. Bray directly owns options to purchase 893,017 shares of BioLargo common stock.
- A Limited Power of Attorney was executed on November 1, 2022, appointing John R. Browning as attorney-in-fact for Section 16 reporting obligations.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction (stock option grant) and doesn't contain any alarming or negative information. It's a neutral event with a slightly positive sentiment due to aligning director interests with shareholders.
Positives
- The issuance of stock options aligns the director's interests with those of the shareholders.
- The compensation structure helps conserve the company's cash reserves.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Granting stock options to board members is a common practice in publicly traded companies to align their interests with shareholders and conserve cash.
Comparison to Industry Standards
- Stock option grants to directors are a standard form of compensation, often benchmarked against peer companies of similar size and industry.
- The specific number of options and exercise price would be determined by the company's compensation policy and market conditions.
Related Party Transactions
- The grant of stock options to Christina Bray, a director, is a related party transaction.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the director's interests with the company's performance.
- Employees may see it as a standard compensation practice.
Key Dates
| Date | Description |
|---|---|
| 2022-11-01 | Date of Limited Power of Attorney execution. |
| 2024-12-31 | Date of transaction: Grant of stock options to Christina Bray. |
| 2034-12-31 | Expiration date of the granted stock options. |
| 2025-01-03 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.